<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535989</url>
  </required_header>
  <id_info>
    <org_study_id>IOSI-LND-001</org_study_id>
    <nct_id>NCT01535989</nct_id>
  </id_info>
  <brief_title>Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma</brief_title>
  <acronym>IOSI-LND-001</acronym>
  <official_title>A Phase I Study of Inotuzumab Ozogamicin (CMC-544) in Combination With Temsirolimus (CCI-779) in Patients With Relapsed or Refractory CD22-positive B-cell Non Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristiana Sessa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncology Institute of Southern Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase I study of Inotuzumab Ozogamicin, an antibody-targeted
      intravenous chemotherapy agent composed of a CD22-targeted antibody linked to calicheamicin,
      in combination with the mammalian target of rapamycin (mTOR) inhibitor Temsirolimus, in
      patients with relapsed/refractory CD22+ B-cell non Hodgkin's lymphomas (NHLs). Both
      Inotuzumab Ozogamicin and Temsirolimus have been evaluated as single agents as well as in
      combination with rituximab in patients with NHLs. This is the first study combining the two
      agents together. In the present study Inotuzumab Ozogamicin will be administered
      intravenously on d1 at the starting dose of 0.8 /m2. Temsirolimus will be administered
      intravenously on days 1,8,15 and 22 at the starting dose of 15mg. Cycles will be repeated
      every 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants with adverse events based on the CTCAE v.4</measure>
    <time_frame>toxicities will be assessed during the participation of each patient in the study, an expected average of 8 weeks</time_frame>
    <description>To determine the safety profile, establish the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of Inotuzumab Ozogamicin in combination with Temsirolimus in patients with relapsed/refractory CD22+ B-cell NHLs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity based on Cheson criteria</measure>
    <time_frame>after 12-18 months form the first patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>B-cell Lymphoma Refractory</condition>
  <arm_group>
    <arm_group_label>intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin</intervention_name>
    <description>starting dose 0.8 mg/m2, d1 administration, q4wks</description>
    <arm_group_label>intravenous</arm_group_label>
    <other_name>CMC-544</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>starting dose of 15mg, weekly administration, q4ws</description>
    <arm_group_label>intravenous</arm_group_label>
    <other_name>Torisel, CCI-779</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria

          -  Histologically and/or cytologically confirmed relapsed or refractory CD22+ B-cell Non
             Hodgkin's Lymphomas

          -  No limitations on prior treatments. Patients must have progressed after at least one
             prior therapy.

          -  Adult patients (aged &gt; 18yrs old).

          -  ECOG status ≤ 1.

          -  Life expectancy greater than 3 months.

          -  Adequate organ and marrow function.

        Key exclusion criteria

          -  Uncontrolled intercurrent illness

          -  Chronic obstructive or chronic restrictive pulmonary disease

          -  Hepatitis B, C and HIV

          -  Patients with known known central nervous system lymphoma involvement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios Stathis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InselSpital, Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>San Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Cristiana Sessa</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>B-cell Non Hodgkin's Lymphomas</keyword>
  <keyword>CD22 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

